NCT07198555View on ClinicalTrials.gov

A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of BBM-A101 in the Treatment of Knee Osteoarthritis.

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

October 9, 2025

Primary Completion Date

December 30, 2027

Study Completion Date

December 30, 2031

Conditions
Knee Osteoarthritis
Interventions
DRUG

BBM-A101

"Single-dose intra-articular （IA）injection （2ml）(phase Ia)~Low dose group， Middle dose group； High dose group； Control group ：Placebo"

DRUG

Placebo

Placebo(phase Ia)

DRUG

BBM-A101

"Single-dose intra-articular （IA）injection （2ml）(phase Ib) Low dose group， High dose group~Control group ：Placebo"

DRUG

Placebo

Placebo（phase Ib）

Trial Locations (2)

200011

The Ninth People's Hospital of Shanghai Jiao Tong University School of Medicine, Shanghai

518035

Shenzhen Second People's Hospital, Shenzhen

All Listed Sponsors
lead

Belief BioMed (Beijing) Co., Ltd

INDUSTRY

NCT07198555 - A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of BBM-A101 in the Treatment of Knee Osteoarthritis. | Biotech Hunter | Biotech Hunter